Mirati Therapeutics, Inc. (MRTX)
Stock Price:
$131.59 USD
5.78 (4.59%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
5.86B |
| Revenue (ttm) |
1.78M |
| Net Income (ttm) |
-296.16M |
| Shares Out |
44.54M |
| EPS (ttm) |
-7.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$131.59 |
| Previous Close |
$125.81 |
| Change ($) |
5.78 |
| Change (%) |
4.59% |
| Day's Open |
126.67 |
| Day's Range |
125.92 - 132.98 |
| Day's Volume |
271,317 |
| 52-Week Range |
66.01 - 137.29 |
More Stats
| Market Cap |
5.86B |
| Enterprise Value |
5.22B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.54M |
| Float |
30.15M |
| EPS (basic) |
-7.15 |
| EPS (diluted) |
-7.16 |
| FCF / Share |
-4.47 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.99M |
| Short Ratio |
15.90 |
| Short % of Float |
12.99% |
| Beta |
1.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3,290.91 |
| PB Ratio |
9.63 |
| Revenue |
1.78M |
| Operating Income |
-306.06M |
| Net Income |
-296.16M |
| Free Cash Flow |
-196.03M |
| Net Cash |
645.71M |
| Net Cash / Share |
14.50 |
| Gross Margin |
187.25% |
| Operating Margin |
-17,184.50% |
| Profit Margin |
-16,629.00% |
| FCF Margin |
-11,006.79% |
| ROA |
-32.83% |
| ROE |
-54.97% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (14)
| Buy |
13 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$141.62*
(7.62% upside)
Low
101
Current: $131.59
High
163
Target: 141.62
*Average 12-month price target from 13 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 3.34 | 12.93 | - | - | - | - | - | - | 3.14 |
| Revenue Growth | -74.2% | - | - | - | - | - | - | - | - |
| Gross Profit | 3.34 | 12.93 | - | - | - | - | - | - | 3.14 |
| Operating Income | -222 | -103 | -71.54 | -83.78 | -64.71 | -39.10 | -32.00 | -20.50 | -10.09 |
| Net Income | -213 | -98.42 | -70.43 | -83.12 | -64.54 | -43.70 | -52.86 | -20.29 | -9.78 |
| Shares Outstanding | 37.47 | 30.90 | 25.29 | 19.79 | 16.90 | 13.48 | 11.06 | 6.76 | 4.94 |
| Earnings Per Share | -5.69 | -3.19 | -2.78 | -4.20 | -3.82 | -3.24 | -4.78 | -3.00 | -1.98 |
| Operating Cash Flow | -148 | -70.10 | -64.71 | -68.02 | -50.71 | -32.75 | -29.46 | -16.65 | -11.64 |
| Capital Expenditures | -1.55 | -0.12 | -0.08 | -0.20 | -0.33 | -0.39 | -0.20 | -0.23 | -0.03 |
| Free Cash Flow | -149 | -70.22 | -64.79 | -68.21 | -51.04 | -33.13 | -29.66 | -16.88 | -11.68 |
| Cash & Equivalents | 415 | 223 | 151 | 56.73 | 122 | 29.30 | 62.07 | 36.98 | 28.74 |
| Net Cash / Debt | 415 | 223 | 151 | 56.73 | 122 | 29.30 | 62.07 | 36.98 | 28.74 |
| Assets | 432 | 228 | 157 | 63.44 | 128 | 33.48 | 64.54 | 39.80 | 31.08 |
| Liabilities | 49.91 | 26.88 | 13.96 | 15.14 | 9.84 | 5.42 | 38.65 | 5.39 | 3.78 |
| Book Value | 382 | 202 | 143 | 48.31 | 118 | 28.06 | 25.89 | 34.42 | 27.31 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Mirati Therapeutics, Inc. |
| Country |
United States |
| Employees |
111 |
| CEO |
Charles M. Baum |
Stock Information
| Ticker Symbol |
MRTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MRTX |
| IPO Date |
June 29, 2004 |
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.